GSK bolsters vaccine business with Merck cast-off
GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.
GlaxoSmithKline has acquired Swiss vaccine developer Okairos for €250 million in cash. The privately held firm was spun out of Merck & Co in 2007.